|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Allergan
|
|
gptkbp:acquisitionYear
|
2020
|
|
gptkbp:CEO
|
gptkb:Richard_A._Gonzalez
|
|
gptkbp:countryOfOrigin
|
gptkb:United_States
|
|
gptkbp:dividendPaying
|
yes
|
|
gptkbp:founded
|
2013
|
|
gptkbp:foundedBy
|
gptkb:Abbott_Laboratories
|
|
gptkbp:headquartersLocation
|
gptkb:North_Chicago,_Illinois,_United_States
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
US00287Y1091
|
|
gptkbp:marketCap
|
over $250 billion (2024)
|
|
gptkbp:memberOf
|
gptkb:S&P_500
gptkb:S&P_100
|
|
gptkbp:netIncome
|
$4.87 billion (2023)
|
|
gptkbp:notable_executive
|
gptkb:Azita_Saleki-Gerhardt
gptkb:Carlos_Alban
gptkb:Henry_O._Gosebruch
gptkb:Jeffrey_R._Stewart
gptkb:Laura_Schumacher
gptkb:Michael_E._Severino
gptkb:Nicholas_Donoghoe
gptkb:Robert_A._Michael
gptkb:Roopal_Thakkar
gptkb:Thomas_C._Hudson
gptkb:Timothy_J._Richmond
gptkb:William_J._Chase
|
|
gptkbp:notablePatentLitigation
|
Humira biosimilars
|
|
gptkbp:notableProduct
|
gptkb:Humira
gptkb:Imbruvica
gptkb:Rinvoq
gptkb:Skyrizi
gptkb:Venclexta
|
|
gptkbp:numberOfEmployees
|
~50,000
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:researchFacilityLocation
|
gptkb:Redwood_City,_California,_United_States
gptkb:Worcester,_Massachusetts,_United_States
gptkb:Ludwigshafen,_Germany
gptkb:Lake_County,_Illinois,_United_States
|
|
gptkbp:revenue
|
$58.05 billion (2023)
|
|
gptkbp:SIC
|
2834
|
|
gptkbp:spinOff
|
gptkb:Abbott_Laboratories
|
|
gptkbp:stockSymbol
|
gptkb:NYSE
gptkb:ABBV
|
|
gptkbp:therapeuticArea
|
aesthetics
immunology
neuroscience
oncology
gastroenterology
virology
eye care
|
|
gptkbp:tradedOn
|
gptkb:NYSE
|
|
gptkbp:website
|
https://www.abbvie.com/
|
|
gptkbp:bfsParent
|
gptkb:Caribou_Biosciences
gptkb:Cystic_Fibrosis_Foundation
gptkb:Infinity_Pharmaceuticals
gptkb:Ironwood_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AbbVie
|